Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

Fig. 1

Model diagram. ALK: anaplastic lymphoma kinase IHC: immunohistochemistry; FISH: fluorescent in situ hybridization; NGS: next-generation sequencing; TP: True positive; FP: false positive; TN: true negative; FN: false negative; EGFR:epidermal growth factor receptor; WT: wild-type; TPS: tumor proportion score TKI: tyrosine kinase inhibitors; PFS: progression-free survival PD: progressed-disease. a Chemoterapy: cisplatin+pemetrexed; carbolplatin+paclitaxel+bevacizumab; cisplatin+pemetrexed+pembrolizumab

Back to article page